Humanized Mouse and Rat Model Market Size, Global Industry Analysis by Trends, Future Demands, Top Key Players and Forecast till 2027

The Global Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market include increasing number of research activities involving humanized models, growing demand for personalized medicine, continuous support in the form of investments and grants from the government and private sector, rising usage of mice models in virology and infectious disease testing, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies. However, the high cost of humanized mouse and rat models and regulations & laws regarding the ethical use of animals in medical research are expected to restrain the growth of this market during the forecast period.

Humanized Mouse Model Market

Download PDF Brochure:

Global Humanized Mouse and Rat Model Market Dynamics

DRIVER: Increasing research activities using humanized models

Continuous research is being undertaken for the development of treatments for immunodeficiency disorders, cancers, and other rare diseases. A majority of these research studies are highly dependent on animal models. Owing to this, market players are continuously focusing on bringing about innovations in mouse models. As highly advanced and innovative mouse models provide increased options to researchers, the demand for such models has increased in the market in recent years.

RESTRAINT: Laws and regulations for the ethical use of animal models in research

Various regulations and laws have been laid down by the government for ensuring the ethical use of animals in research activities. Research institutes and companies carrying out studies on animals have to comply with these standards and requirements formulated for animal testing. In the US, the Animal welfare Act (AWA) and the Public Health Service Policy on Human Care and Use of Laboratory animals (PHS) are two main regulations governing the use of animals in research. The AWA is a federal law covering animals in research. It covers almost 90-95% of animals including rats, mice, and birds, which are bred for research. The US Department of Agriculture (USDA) enforces AWA, according to which businesses and individuals using regukated animals must be licensed or registered with USDA, and facilities with regulated animals must be inspected every year by the Animal and Plant Health Inspection Services (APHIS).

OPPORTUNITY: Rising demand for humanized PDX models

It is observed that xenografts develop well in immunodeficient models, and these immunodeficient models are majorly applied for creating PDX model. Although, these models do not deem fit for evaluating stroma-tumor interactions, and these are highly responsible for growth and progression of tumor in a patient. To overcome these issues Humanized PDX models are gaining popularity in the market.

CHALLENGE: Alternatives for animal testing

Alternative tests to humanized mouse model such as vitro methods and models based on human cells and tissue cultures; computerized patient-drug databases and virtual drug trials; computer models and simulations (in silico models); organs-on-chips; stem cell and genetic testing methods; and non-invasive imaging techniques, such as MRI, CT, and microdosing are reliable, cost-effective, practical, and expedient. It has been observed that the use of human tissue in toxicity testing is more accurate than using animal models. Rodents are predominantly used in toxicity and safety assessment studies. However, substantial efforts are being made to develop alternative testing methods that are accepted internationally. In the European Union, challenging timelines for phasing out several standard tests using laboratory animals were established in the seventh Amending Directive 2003/15/EC to Cosmetics Directive 76/768/EEC. In continuation of this policy, the new European Chemicals Legislation (REACH) favors methods that are alternative to conventional in vivo testing if validated.

Inquiry Before Buying:

Key Market Players:

Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Envigo (US), Vitalstar Biotechnology (China), inGenious Targeting Laboratory (US), AXENIS (France), TRANS GENIC (Japan), Harbour Antibodies (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), GVK BIO (India), and Biocytogen (US).

The North American market is projected to contribute the largest share for the humanized mouse and rat model market

The global market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for market in 2022, while Europe is the second-largest market. The major factors driving the growth of the North American market include the presence of a well-established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of clinical testing by pharmaceutical and biotechnology companies in the region. Also, there is a rising focus on oncology research in the US, government support for the development of protein drugs, and growing stem cell research in Canada. These factors are boosting the demand for humanized mouse and rat models in North America.

Recent Developments

  • In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
  • In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan’s Research Models & Services (RMS) business as a wholly-owned subsidiary.
  • In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
  • In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River’s broad capabilities across the major CDMO platforms for cell and gene therapies.

Get 10% Free Customization on this Report:

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.


Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441


Research Insight:

Visit Our Website:

Content Source: